황반변성증 치료 시장 규모, 점유율, 성장 분석 : 유형별, 치료법별, 질병 단계별, 투여 경로별, 지역별 - 산업 예측(2025-2032년)

Global Macular Degeneration Treatment Market size was valued at USD 16.7 billion in 2023 and is poised to grow from USD 18.12 billion in 2024 to USD 34.8 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The global macular degeneration treatment market is rapidly evolving, driven by the increasing prevalence of age-related macular degeneration (AMD) and a rising elderly population. As the demand for effective therapeutic solutions grows, notable advancements in medical research, including innovative anti-VEGF therapies and sustained-release drug delivery systems, have improved patient outcomes. Key market trends highlight the rise of combination therapies, targeting multiple disease pathways, and promising gene therapy approaches that address genetic factors. However, challenges such as high treatment costs, limited reimbursement coverage, and stringent regulatory requirements persist. Notably, emerging markets in Asia-Pacific and Latin America present significant growth opportunities, while the integration of artificial intelligence and machine learning technologies promises to enhance diagnostics and treatment, paving the way for personalized medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macular Degeneration Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macular Degeneration Treatment Market Segmental Analysis

Global Macular Degeneration Treatment Market is segmented by Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration and Others. Based on Treatment, the market is segmented into Anti-vascular Endothelial and Others. Based on Stage of Disease, the market is segmented into Early-stage AMD, Intermediate AMD and Late-stage AMD. Based on Route of Administration, the market is segmented into Intravenous Route and Intravitreal Route. Based on Distribution Channel, the market is segmented into Ambulatory Surgical Centres, Hospitals and Other Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macular Degeneration Treatment Market

The macular degeneration treatment market is significantly influenced by the growing aging population. As macular degeneration predominantly impacts individuals over 50, the rise in the global elderly demographic is anticipated to escalate the incidence of this condition. The World Health Organization has projected that the population aged 60 and above will double by 2050. This demographic transformation is poised to enhance the demand for effective treatments targeting macular degeneration, driving market growth. Consequently, healthcare providers and pharmaceutical companies are increasingly focused on developing innovative therapies to address the needs of this expanding population segment, ultimately fostering advancements in treatment options.

Restraints in the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market faces several restraints, one of which is the stringent regulatory requirements that govern the industry. The process for obtaining approval for new treatment options is often protracted and can impose significant costs on pharmaceutical companies. This involves extensive clinical trials, rigorous safety assessments, and detailed regulatory submissions, all of which can hinder the timely introduction of novel therapies. Consequently, the intricate regulatory landscape may discourage some companies from investing in research and development for macular degeneration treatments, ultimately restricting the range and availability of innovative solutions for patients suffering from this condition.

Market Trends of the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market is increasingly influenced by the rise of telemedicine and remote monitoring technologies, which have revolutionized patient care in this sector. The shift towards these digital healthcare solutions facilitates remote assessments of vision and disease progression, minimizing the necessity for frequent in-person consultations. This trend not only enhances patient convenience and compliance but also enables timely interventions and effective disease management, ultimately driving down healthcare costs. Innovations such as home-based visual acuity testing and smartphone imaging devices are becoming integral in monitoring treatment efficacy and disease developments, underscoring a transformative move towards more accessible and efficient care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Macular Degeneration Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration
• Others

Global Macular Degeneration Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Anti-vascular Endothelial
• Others

Global Macular Degeneration Treatment Market Size by Stage of Disease & CAGR (2025-2032)

• Market Overview
• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Global Macular Degeneration Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous Route
• Intravitreal Route

Global Macular Degeneration Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Ambulatory Surgical Centres
• Hospitals
• Other Channels

Global Macular Degeneration Treatment Market Size & CAGR (2025-2032)

• North America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PanOptica (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olix Pharmaceuticals Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONL Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OnPoint Vision Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations